| Triple-negative breast cancer(TNBC)is a malignant tumor that does not express ER,PR,or HER2,accounting for about one-fifth of all breast cancer types.TNBC is characterized by rapid tumor growth,rapid recurrence and natural metastasis.Recently,the abnormal expression of some lncRNAs has been suggested to be associated with malignancy in mammals,especially cancer.LncRNAs may play an important role in the occurrence of TNBC,and further exploration of lncRNAs that may be involved in the event of TNBC could provide a new target for the diagnosis and prognostic detection of triple-negative breast cancer.We analyzed the PAM50 subtype of 2950 samples from 13 breast cancer expression datasets from GEO and analyzed the differences between them and normal breast tissue samples in pairs.By eliminating the same differential genes,a total of 3484 differential genes that were unique in TNBC tissues were selected(p<0.05).Weighted co-expression network analysis of these genes identified that the blue module gene sets were most associated with TNBC(cor=0.38,p=6e-14).By screening 200 genes in the blue module(MM>0.8),54 key central genes were obtained,including five lncRNAs: LINC00337,OSTM1-AS1,DEPDC1-AS1,DDX11-AS1 and LINC00608.Functional enrichment analysis of 54 central genes was conducted to provide suggestions for possible biological pathways.Based on TCGA-based expression data,we determined that LINC00337(p<2e-16),DEPDC1-AS1(p<2e-16)and DDX11-AS1(p<2e-16)were lncRNAs that were more associated with TNBC.Multivariate Cox regression was used to establish a 3-lncRNA risk scoring model.Kaplan-Meier survival analysis and ROC curves analysis in GEO TNBC data showed that this model had a good prognostic ability(HR:2.72;(1.34-5.51),p=0.006).In addition,the predictive ability of the model was verified in TCGA TNBC data(HR:4.07;(1.1-15.11),p=0.036).In summary,we obtained 3 characteristic lncRNAs of TNBC through data analysis and we also established a 3-lncRNA model for predicting the risk of TNBC,there will provide theoretical basis for the treatment and prognosis evaluation of clinical TNBC. |